EVOLUS, INC. Operating Expenses
EVOLUS, INC. (EOLS) reported Operating Expenses of $21.57 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-10-29
- EVOLUS, INC. operating expenses for the quarter ending 2020-09-30 was $21.57M, a 37.64% decline year-over-year.
- EVOLUS, INC. operating expenses for the quarter ending 2020-06-30 was $24.75M, a 34.27% decline year-over-year.
- EVOLUS, INC. operating expenses for the quarter ending 2020-03-31 was $23.67M, a 6.32% decline year-over-year.
- EVOLUS, INC. operating expenses for the quarter ending 2019-12-31 was $28.35M, a 126.69% increase year-over-year.
- EVOLUS, INC. operating expenses for fiscal 2019 was $125.86M, a 172.76% increase from fiscal 2018.
- EVOLUS, INC. operating expenses for fiscal 2018 was $46.14M, a 293.50% increase from fiscal 2017.
- EVOLUS, INC. operating expenses for fiscal 2017 was $11.73M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-09-30 | $21.57M 10-Q · filed 2020-10-29 | $46.31M derived: sum of 2 quarters · filed 2020-10-29 | $69.98M 10-Q · filed 2020-10-29 | $98.34M derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $24.75M 10-Q · filed 2020-08-10 | $48.42M 10-Q · filed 2020-08-10 | $76.77M derived: sum of 3 quarters · filed 2020-08-10 | $111.36M derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $23.67M 10-Q · filed 2020-05-11 | $52.03M derived: sum of 2 quarters · filed 2020-05-11 | $86.61M derived: sum of 3 quarters · filed 2020-10-29 | $124.26M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | $28.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $62.94M derived: sum of 2 quarters · filed 2020-10-29 | $100.59M derived: sum of 3 quarters · filed 2020-10-29 | $125.86M 10-K · filed 2020-02-25 |
| 2019-09-30 | $34.59M 10-Q · filed 2020-10-29 | $72.23M derived: sum of 2 quarters · filed 2020-10-29 | $97.50M 10-Q · filed 2020-10-29 | $110.01M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $37.65M 10-Q · filed 2020-08-10 | $62.92M 10-Q · filed 2020-08-10 | $75.42M derived: sum of 3 quarters · filed 2020-08-10 | $86.91M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $25.27M 10-Q · filed 2020-05-11 | $37.78M derived: sum of 2 quarters · filed 2020-05-11 | $49.27M derived: sum of 3 quarters · filed 2020-05-11 | $65.37M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $12.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $24.00M derived: sum of 2 quarters · filed 2020-02-25 | $40.10M derived: sum of 3 quarters · filed 2020-02-25 | $46.14M 10-K · filed 2020-02-25 |
| 2018-09-30 | $11.49M 10-Q · filed 2019-11-04 | $27.59M derived: sum of 2 quarters · filed 2019-11-04 | $33.63M 10-Q · filed 2019-11-04 | $36.49M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $16.10M 10-Q · filed 2019-08-12 | $22.14M 10-Q · filed 2019-08-12 | $25.00M derived: sum of 3 quarters · filed 2019-08-12 | $27.62M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $6.04M 10-Q · filed 2019-05-01 | $8.90M derived: sum of 2 quarters · filed 2019-05-01 | $11.52M derived: sum of 3 quarters · filed 2019-05-01 | $13.79M derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $5.47M derived: sum of 2 quarters · filed 2019-03-20 | $7.75M derived: sum of 3 quarters · filed 2019-03-20 | $11.73M 10-K · filed 2019-03-20 |
| 2017-09-30 | $2.62M 10-Q · filed 2018-11-05 | $4.89M derived: sum of 2 quarters · filed 2018-11-05 | $8.87M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $2.27M 10-Q · filed 2018-08-02 | $6.25M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $3.98M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |